Fig. 4

Non-matched therapy as post-osimertinib treatment for LM. A Comparison of overall survival between osimertinib 80 mg combination (chemotherapy/bevacizumab/radiotherapy) and regimen switch. B Comparison of overall survival between osimertinib 80 mg combination (chemotherapy/bevacizumab/radiotherapy) and regimen switch in those with central-nervous-system-only progression. C Clinical response and survival outcome of osimertinib 80 mg combination, dose escalation, osimertinib 160 mg combination, continuing osimertinib 80 mg, and regimen switch. mo, months; chemo, chemotherapy; bev, bevacizumab; RT, radiotherapy; RR: response rate (clinical); OS, overall survival